Company intelligence / Profile preview

GenuPro

United States

Ownership: Private
Development stage: Other

Overview

GenPro develops epigenetic biomarkers and clinical assays for patient stratification, early disease detection, diagnostics, and monitoring; demonstrated through partnerships in oncology, neurology, neurodegenerative diseases, and endometriosis. No therapeutic clinical trial results available.

Therapeutic areas: OncologyNeurologyWomen's Health
Modalities: Diagnostic testBiologicAssay
Industry: Molecular Diagnostics

Partnerships

Biopharma/biotech industry partners (details not disclosed)Clinical research institutions

Beyond the preview

Go deeper on GenuPro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenuPro.

Explore the full profile